Does health technology assessment compromise access to pharmaceuticals?
AMNOG
HTA
Health policy
Launch delay
Pharmaceuticals
Price regulation
Journal
The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
30
11
2021
accepted:
17
05
2022
medline:
31
3
2023
pubmed:
17
6
2022
entrez:
16
6
2022
Statut:
ppublish
Résumé
In response to rapidly rising pharmaceutical costs, many countries have introduced health technology assessment (HTA) as a 'fourth hurdle'. We evaluated the causal effect of HTA based regulation on access to pharmaceuticals by using the introduction of Germany's HTA system (AMNOG) in 2011. We obtained launch data on pharmaceuticals for 30 European countries from the IQVIA (formerly IMS) database. Using difference-in-difference models, we estimated the effect of AMNOG on launch delay, the ranking order of launch delays, and the availability of pharmaceuticals. We then compared the results for Germany to Austria, Czechia, Italy, Portugal, and the UK. Across all six countries, launch delays decreased from the pre-AMNOG period (25.01 months) to the post-AMNOG period (14.34 months). However, the introduction of AMNOG consistently reduced the magnitude of the decrease in launch delay in Germany compared to the comparator countries (staggered DiD: + 4.31 months, p = 0.05). Our logit results indicate that the availability of pharmaceuticals in Germany increased as a result of AMNOG (staggered logit: + 5.78%, p = 0.009). We provide evidence on the trade-off between regulation and access. This can help policymakers make better-informed decisions to strike the right balance between cost savings achieved through HTA based regulation and access to pharmaceuticals.
Identifiants
pubmed: 35708786
doi: 10.1007/s10198-022-01484-4
pii: 10.1007/s10198-022-01484-4
pmc: PMC10060338
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
437-451Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
Lee, Y.S.: Value-based health technology assessment and health informatics. Healthc Inform Res (2017). https://doi.org/10.4258/hir.2017.23.3.139
doi: 10.4258/hir.2017.23.3.139
pubmed: 29181245
pmcid: 5688035
Angelis, A., Lange, A., Kanavos, P.: Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ 19(1), 123–152 (2018). https://doi.org/10.1007/s10198-017-0871-0
doi: 10.1007/s10198-017-0871-0
pubmed: 28303438
Olberg, B., Fuchs, S., Panteli, D., Perleth, M., Busse, R.: Scientific evidence in health technology assessment reports: an in-depth analysis of european assessments on high-risk medical devices. Value Health 20(10), 1420–1426 (2017). https://doi.org/10.1016/j.jval.2017.05.011
doi: 10.1016/j.jval.2017.05.011
pubmed: 29241902
Lauenroth, V.D., Stargardt, T.: Pharmaceutical pricing in germany: how is value determined within the scope of AMNOG? Value Health 20(7), 927–935 (2017). https://doi.org/10.1016/j.jval.2017.04.006
doi: 10.1016/j.jval.2017.04.006
pubmed: 28712622
Akehurst, R.L., Abadie, E., Renaudin, N., Sarkozy, F.: Variation in health technology assessment and reimbursement processes in Europe. Value Health 20(1), 67–76 (2017). https://doi.org/10.1016/j.jval.2016.08.725
doi: 10.1016/j.jval.2016.08.725
pubmed: 28212972
Wilking, N., Jönsson, B.: A pan-European comparison regarding patient access to cancer drugs. Karolinska Institutet Stockholm, Sweden (2005)
Lichtenberg, F.R.: The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982–2001. Int J Health Care Finance Econ (2005). https://doi.org/10.1007/s10754-005-6601-7
doi: 10.1007/s10754-005-6601-7
pubmed: 15714263
Zhu, X., Liu, B.: Launch delay of new drugs in china and effect on patients’ health. Clin Ther 42(9), 1750-1761.e7 (2020). https://doi.org/10.1016/j.clinthera.2020.06.023
doi: 10.1016/j.clinthera.2020.06.023
pubmed: 32798058
Schöffski, O.: Diffusion of medicines in Europe. Health Economic Research Zentrum, Burgdorf (2002)
Danzon, P.M., Ketcham, J.D.: Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand. Front Health Policy Res 7, 1–54 (2004). https://doi.org/10.2202/1558-9544.1050
doi: 10.2202/1558-9544.1050
pubmed: 15612334
Kessler, D.P.: The effects of pharmaceutical price controls on the cost and quality of medical care: a review of the empirical literature. Citeseer (2004)
Wertheimer und Santella, “[PDF] Pharmacoevolution : the advantages of incremental innovation | Semantic Scholar“. https://www.semanticscholar.org/paper/Pharmacoevolution-%3A-the-advantages-of-incremental-Wertheimer/3c0ea81a136fc623e3c32080b3ef95f44eb0a07c (zugegriffen 25 Nov 2020).
Bhaduri, S., Brenner, T.: Examining the determinants of drug launch delay in pre-TRIPS India. Eur J Health Econ 14(5), 761–773 (2013)
doi: 10.1007/s10198-012-0422-7
pubmed: 22961229
Dranove, D., Meltzer, D.: Do Important Drugs Reach the Market Sooner? Rand J Econ 25(3), 402–423 (1994). https://doi.org/10.2307/2555769
doi: 10.2307/2555769
Peltzman, S.: An evaluation of consumer protection legislation: the 1962 drug amendments. J Polit Econ (2015). https://doi.org/10.1086/260107
doi: 10.1086/260107
Danzon, P.M., Wang, Y.R., Wang, L.: The impact of price regulation on the launch delay of new drugs–evidence from twenty-five major markets in the 1990s. Health Econ 14(3), 269–292 (2005). https://doi.org/10.1002/hec.931
doi: 10.1002/hec.931
pubmed: 15386651
Fischer, K.E., Stargardt, T.: Early benefit assessment of pharmaceuticals in germany: manufacturers’ expectations versus the federal joint committee’s decisions. Med Decis Making 34(8), 1030–1047 (2014). https://doi.org/10.1177/0272989X14546377
doi: 10.1177/0272989X14546377
pubmed: 25149822
Garattini, L., Ghislandi, S.: Should we really worry about “launch delays” of new drugs in OECD countries? Eur J Health Econ 8(1), 1–3 (2007). https://doi.org/10.1007/s10198-006-0022-5
doi: 10.1007/s10198-006-0022-5
pubmed: 17186203
Cohen, J., Faden, L., Predaris, S., Young, B.: Patient access to pharmaceuticals: an international comparison. Eur J Health Econ 8(3), 253–266 (2007). https://doi.org/10.1007/s10198-006-0028-z
doi: 10.1007/s10198-006-0028-z
pubmed: 17279403
Degrassat-Théas, A., Paubel, P., Parent de Curzon, O., Le Pen, C., Sinègre, M.: Temporary authorization for use: does the french patient access programme for unlicensed medicines impact market access after formal licensing? Pharmacoeconomics 31(4), 335–343 (2013). https://doi.org/10.1007/s40273-013-0039-4
doi: 10.1007/s40273-013-0039-4
pubmed: 23529210
Russo, P., Mennini, F.S., Siviero, P.D., Rasi, G.: Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Ann Oncol 21(10), 2081–2087 (2010). https://doi.org/10.1093/annonc/mdq097
doi: 10.1093/annonc/mdq097
pubmed: 20335370
Ferrario, A.: Time to entry for new cancer medicines: from European union-wide marketing authorization to patient access in Belgium, Estonia, Scotland, and Sweden. Value Health 21(7), 809–821 (2018). https://doi.org/10.1016/j.jval.2018.01.003
doi: 10.1016/j.jval.2018.01.003
pubmed: 30005753
Cohen, J., Cairns, C., Paquette, C., Faden, L.: Comparing patient access to pharmaceuticals in the UK and US. Appl Health Econ Health Policy 5(3), 177–187 (2006). https://doi.org/10.2165/00148365-200605030-00004
doi: 10.2165/00148365-200605030-00004
pubmed: 17132032
Paris, V., Belloni, A.: Value in pharmaceutical pricing. Juli (2013). https://doi.org/10.1787/5k43jc9v6knx-en
doi: 10.1787/5k43jc9v6knx-en
Fischer, K.E., Heisser, T., Stargardt, T.: Health benefit assessment of pharmaceuticals: an international comparison of decisions from Germany, England, Scotland and Australia. Health Policy 120(10), 1115–1122 (2016). https://doi.org/10.1016/j.healthpol.2016.08.001
doi: 10.1016/j.healthpol.2016.08.001
pubmed: 27628196
Detiček, A., Locatelli, I., Kos, M.: Patient Access to medicines for rare diseases in european countries. Value Health 21(5), 553–560 (2018). https://doi.org/10.1016/j.jval.2018.01.007
doi: 10.1016/j.jval.2018.01.007
pubmed: 29753352
Greiner, W., Patel, K., Crossman-Barnes, C.-J., Rye-Andersen, T.V., Hvid, C., Vandebrouck, T.: High-expenditure disease in the EU-28: does drug spend correspond to clinical and economic burden in oncology, autoimmune disease and diabetes? Pharmacoecon Open (2021). https://doi.org/10.1007/s41669-020-00253-4
doi: 10.1007/s41669-020-00253-4
pubmed: 33411314
pmcid: 8333173
Kim, Y., Kwon, H.-Y., Godman, B., Moorkens, E., Simoens, S., Bae, S.: Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries? Front Pharmacol 11, 970 (2020). https://doi.org/10.3389/fphar.2020.00970
doi: 10.3389/fphar.2020.00970
pubmed: 32733238
pmcid: 7363801
Führlinger, S.: Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria. Wien Med Wochenschr (2006). https://doi.org/10.1007/s10354-006-0357-7
doi: 10.1007/s10354-006-0357-7
pubmed: 17211765
Gulácsi, L., et al.: Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ 15(1), 13–25 (2014). https://doi.org/10.1007/s10198-014-0590-8
doi: 10.1007/s10198-014-0590-8
Ciani, O., Tarricone, R., Torbica, A.: Diffusion and use of health technology assessment in policy making: what lessons for decentralised healthcare systems? Health Policy 108(2), 194–202 (2012). https://doi.org/10.1016/j.healthpol.2012.09.017
doi: 10.1016/j.healthpol.2012.09.017
pubmed: 23093020
Infarmed. https://www.infarmed.pt/ (zugegriffen 8 Feb 2021).
NICE|The National Institute for Health and Care Excellence“, NICE. https://www.nice.org.uk/ (zugegriffen 1. Feb 2021).
Startseite-Gemeinsamer Bundesausschuss“. https://www.g-ba.de/ (zugegriffen 10 Mär 2021).
Summerhayes, M., Catchpole, P.: Has NICE been nice to cancer? Eur J Cancer 42(17), 2881–2886 (2006). https://doi.org/10.1016/j.ejca.2006.08.013
doi: 10.1016/j.ejca.2006.08.013
pubmed: 17070032
Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J., Garau, M.: Comparing access to orphan medicinal products in Europe. Orphanet J Rare Dis 14(1), 95 (2019). https://doi.org/10.1186/s13023-019-1078-5
doi: 10.1186/s13023-019-1078-5
pubmed: 31053154
pmcid: 6499954
Danzon, P., Epstein, A.: Effects of regulation on drug launch and pricing in interdependent markets. Adv Health Econ Health Serv Res 23, 35–71 (2012). https://doi.org/10.1108/S0731-2199(2012)0000023005
doi: 10.1108/S0731-2199(2012)0000023005
pubmed: 23156660
Stargardt, T., Schreyögg, J.: Impact of cross-reference pricing on pharmaceutical prices: manufacturers’ pricing strategies and price regulation. Appl Health Econ Health Policy 5(4), 235–247 (2006). https://doi.org/10.2165/00148365-200605040-00005
doi: 10.2165/00148365-200605040-00005
pubmed: 17249840
Arzneimittelmarktneuordnungsgesetz (AMNOG), Bundesgesundheitsministerium. https://www.bundesgesundheitsministerium.de/service/begriffe-von-a-z/a/arzneimittelmarktneuordnungsgesetz-amnog.html (zugegriffen 1 Feb 2021).
Sattelmeier, J., Prenzler, A., Frank, M.: Das Arzneimittelmarktneuordnungsgesetz (AMNOG) in der Praxis–erste Erfahrungen, Kritikpunkte und Weiterentwicklungsmöglichkeiten. Health Econ Qual Manag (2013). https://doi.org/10.1055/s-0033-1350528
doi: 10.1055/s-0033-1350528
Staab, T.R., et al.: Market withdrawals‘ of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. Health Econ Rev 8(1), 23 (2018). https://doi.org/10.1186/s13561-018-0209-3
doi: 10.1186/s13561-018-0209-3
pubmed: 30229501
pmcid: 6755547
Blankart, K.E., Stargardt, T.: The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. Health Econ 29(1), 63–82 (2020). https://doi.org/10.1002/hec.4108
doi: 10.1002/hec.4108
pubmed: 32542875
Staab, T.R., et al.: “Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. Health Econ Rev 8(1), 23 (2018). https://doi.org/10.1186/s13561-018-0209-3
doi: 10.1186/s13561-018-0209-3
pubmed: 30229501
pmcid: 6755547
Stern, A.D., Pietrulla, F., Herr, A., Kesselheim, A.S., Sarpatwari, A.: The impact of price regulation on the availability of new drugs in Germany. Health Aff (Millwood) 38(7), 1182–1187 (2019). https://doi.org/10.1377/hlthaff.2018.05142
doi: 10.1377/hlthaff.2018.05142
pubmed: 31260362
Vogler, S., et al.: How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Appl Health Econ Health Policy 15(3), 307–321 (2017). https://doi.org/10.1007/s40258-016-0300-z
doi: 10.1007/s40258-016-0300-z
pubmed: 28063134
Sussell, J., Vanderpuye-Orgle, J., Vania, D., Goertz, H.-P., Lakdawalla, D.: Understanding price growth in the market for targeted oncology therapies. Am J Manag Care 25(6), 273–277 (2019)
pubmed: 31211554
Kantarjian, H., Steensma, D., Sanjuan, J., Elshaug, A., Light, D.: High cancer drug prices in the United States: reasons and proposed solutions. J Oncology Pract (2014). https://doi.org/10.1200/JOP.2013.001351
doi: 10.1200/JOP.2013.001351